［1］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA Cancer J Clin,2021,71(3):209-249.
［2］FERLAY J,SOERJOMATARAM I,DIKSHIT R,et al.Cancer incidence and mortality worldwide:Sources,methods and major patterns in GLOBOCAN 2012［J］.Int J Cancer,2015,136(5):359-386.
［3］周梦龙,章真.局部进展期胃癌术前放疗的优势与思考［J］.外科理论与实践,2019,24(01):23-27.
ZHOU ML,ZHANG Z.Advantages and considerations of preoperative radiotherapy for locally advanced gastric cancer［J］.Surgical Theory and Practice,2019,24(01):23-27.
［4］WANG FH,ZHANG XT,LI YF,et al.The Chinese society of clinical oncology(CSCO):Clinical guidelines for the diagnosis and treatment of gastric cancer,2021［J］.Cancer Commun(Lond),2021，41(8):747-795.
［5］SAKURAMOTO S,SASAKO M,YAMAGUCHI T,et al.Adjuvant chemotherapy for gastric cancer with S-1,an oral fluoropyrimidine［J］.New England Journal of Medicine,2007,357(18):1810-1820.
［6］NOH SH,PARK SR,YANG HK,et al.Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy(CLASSIC):5-year follow-up of an open-label,randomised phase 3 trial［J］.The Lancet Oncology,2014,15(12):1389-1396.
［7］DE VITA F,GIULIANI F,ORDITURA M,et al.Adjuvant chemotherapy with epirubicin,leucovorin,5-fluorouracil and etoposide regimen in resected gastric cancer patients:A randomized phase III trial by the Gruppo Oncologico Italia Meridionale(GOIM 9602 Study)［J］.Ann Oncol,2007,18(8):1354-1358.
［8］DI COSTANZO F,GASPERONI S,MANZIONE L,et al.Adjuvant chemotherapy in completely resected gastric cancer:A randomized phase III trial conducted by GOIRC［J］.J Natl Cancer Inst,2008,100(6):388-398.
［9］BAJETTA E,FLORIANI I,DI BARTOLOMEO M,et al.Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer［J］.Ann Oncol,2014,25(7):1373-1378.
［10］YOSHIKAWA T,TERASHIMA M,MIZUSAWA J,et al.Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer(JCOG1104OPAS-1):An open-label,phase 3,noninferiority,randomised trial［J］.Lancet Gastroenterol Hepatol,2019,4(3):208-216.
［11］KAKEJI Y,YOSHIDA K,KODERA Y,et al.Three-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 plus docetaxel versus S-1 alone in stage III gastric cancer:JACCRO GC-07［J］.Gastric Cancer,2022,25(1):188-196.
［12］WANG XZ,ZENG ZY,YE X,et al.Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines［J］.World J Gastrointest Oncol,2020,12(1):37-53.
［13］CUNNINGHAM D,ALLUM WH,STENNING SP,et al.MAGIC trial participants.Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer［J］.N Engl J Med,2006,355(1):11-20.
［14］YCHOU MARC,BOIGE VALERIE,PIGNON JEAN PIERRE,et al.Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma:An FNCLCC and FFCD multicenter phase III trial［J］.J Clin Oncol,2011,29(13):1715-1721.
［15］AL BATRAN SALAH EDDIN,HOMANN NILS,PAULIGK CLAUDIA,et al.Perioperative chemotherapy with fluorouracil plus leucovorin,oxaliplatin,and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced,resectable gastric or gastro-oesophageal junction adenocarcinoma(FLOT4):A randomised,phase 2/3 trial［J］.Lancet,2019,393(10184):1948-1957.
［16］VAN CUTSEM E,MOISEYENKO VM,TJULANDIN S,et al.Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer:A report of the V325 study group［J］.Journal of Clinical Oncology,2006,24(31):4991-4997.
［17］TERASHIMA M,IWASAKI Y,MIZUSAWA J,et al.Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer,the short-term safety and surgical results:Japan clinical oncology group study(JCOG0501)［J］.Gastric Cancer,2019,22(5):1044-1052.
［18］KANG YK,YOOK JH,PARK YK,et al.PRODIGY:A phase III study of neoadjuvant docetaxel,oxaliplatin,and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant s-1 for resectable advanced gastric cancer［J］.J Clin Oncol,2021,39(26):2903-2913.
［19］ZHANG X,LIANG H,LI Z,et al.RESOLVE study group.Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy(RESOLVE):An open-label,superiority and non-inferiority,phase 3 randomised controlled trial［J］.Lancet Oncol 2021,22(8):1081-1092.
［20］SMALLEY SR,BENEDETTI JK,HALLER DG,et al.Updated analysis of SWOG-directed intergroup study 0116:A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection［J］.J Clin Oncol,2012,30(19):2327-2333.
［21］CATS ANNEMIEKE,JANSEN EDWIN PM,VAN GRIEKEN NICOLE CT,et al.Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer(CRITICS):An international,open-label,randomised phase 3 trial［J］.Lancet Oncol,2018,19(5):616-628.
［22］PARK SH,SOHN TS,LEE J,et al.Phase III trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer:Final report of the adjuvant chemoradiotherapy in stomach tumors trial,including survival and subset analyses［J］.Journal of Clinical Oncology,2015,33(28):3130-3136.
［23］PARK SH,LIM DH,SOHN TS,et al.ARTIST 2 investigators.A randomized phase III trial comparing adjuvant single-agent S1,S-1 with oxaliplatin,and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection:The ARTIST 2 trial［J］.Ann Oncol,2021,32(3):368-374.
［24］KIM HYO SONG,KOOM WOONG SUB,BAEK SONG-EE,et al.Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer［J］.Radiother Oncol,2019,140(11):143-149.
［25］AJANI,WINTER K,OKAWARA GS,et al.Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma(RTOG 9904):Quality of combined modality therapy and pathologic response［J］.Journal of Clinical Oncology,2016,24(24):3953-3958.
［26］LEONG T,SMITHERS BM,HAUSTERMANS K,et al.TOPGEAR:A randomized,phase III trial of perioperative ECF chemotherapy with or without preoperative chemoradiation for resectable gastric cancer:Interim results from an international,intergroup trial of the AGITG,TROG,EORTC and CCTG［J］.Annals of Surgical Oncology,2017,24(8):2252-2258.
［27］GIUSEPPE T,LUCA P,ANGELICA P,et al.What's new in gastric cancer:The therapeutic implications of molecular classifications and future perspectives［J］.International Journal of Molecular Sciences,2018,19(9):2659.
［28］CUNNINGHAM D,STENNING SP,SMYTH EC,et al.Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma(UK medical research council ST03):Primary analysis results of a multicentre,open-label,randomised phase 2-3 trial［J］.Lancet Oncol,2017,18(3):357-370.
［29］杜勇,刘亮华,廖海,等.局部进展期胃癌新辅助化疗治疗进展［J］.中国普外基础与临床杂志,2019,26(11):1385-1392.
DU Y,LIU LH,LIAO H,et al.Advances in neoadjuvant chemotherapy for locally advanced gastric cancer［J］.Chinese Journal of Basic and Clinical General Surgery,2019,26(11):1385-1392.
［30］WAGNER AD,GRABSCH HI,MAUER M,et al.EORTC-1203-GITCG-the' INNOVATION'-trial:Effect of chemotherapy alone versus chemotherapy plus trastuzumab,versus chemotherapy plus trastuzumab plus pertuzumab,in the perioperative treatment of HER2 positive,gastric and gastroesophageal junction adenocarcinoma on pathologic response rate:A randomized phase II-intergroup trial of the EORTC-gastrointestinal tract cancer group,Korean cancer study group and dutch upper GI-cancer group［J］.BMC Cancer,2019,19(1):494.
［31］BANG YJ,VAN CUTSEM E,FUCHS CS,et al.KEYNOTE-585:Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer［J］.Future Oncol,2019,15(9):943-952.
［32］CHUNG HC,ARKENAU HT,LEE J,et al.Avelumab(anti-PD-L1)as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer:Phase 1b results from the JAVELIN solid tumor trial［J］.Journal for ImmunoTherapy of Cancer,2019,7(1):30.
［33］刘华,王雅坤,彭智,等.2019年胃癌治疗盘点：且进步，深思考，再挑战［J］.肿瘤综合治疗电子杂志,2020,6(1):48-52.
LIU H,WANG YK,PENG Z,et al.Review of gastric cancer treatment in 2019:And progress,deep thinking,and then challenge［J］.Electronic Journal of comprehensive cancer therapy,2020,6(1):48-52.
［34］SATO YUYA,KUROKAWA YUKINORI,DOKI YUICHIRO,et al.A phase II study of preoperative chemotherapy with docetaxel,oxaliplatin and S-1 in gastric cancer with extensive lymph node metastasis(JCOG1704)［J］.Future Oncol,2020,16(4):31-38.
［35］TAKAHARI DAISUKE,ITO SEIJI,MIZUSAWA JUNKI,et al.Long-term outcomes of preoperative docetaxel with cisplatin plus S-1 therapy for gastric cancer with extensive nodal metastasis(JCOG1002)［J］.Gastric Cancer,2020,23(2):293-299.
［36］YOSHIKAWA T,MORITA S,TANABE K,et al.Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin(SC)and paclitaxel plus cisplatin(PC)followed by D2 gastrectomy for resectable advanced gastric cancer［J］.Eur J Cancer,2016,62(11):103-111.
［37］SARGENT DANIEL J,MARSONI SILVIA,MONGES GENEVIEVE,et al.Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer［J］.J Clin Oncol,2010,28(20):3219-3226.
［38］SMYTH ELIZABETH C,WOTHERSPOON ANDREW,PECKITT CLARE,et al.Mismatch repair deficiency,microsatellite instability,and survival:An exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy(MAGIC) trial［J］.JAMA Oncol,2017,3(9):1197-1203.
［39］CHOI YOON YOUNG,KIM HYUNKI,SHIN SU JIN,et al.Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer:Post hoc analysis of the CLASSIC randomized controlled study［J］.Ann Surg,2019,270(2):309-316.
［40］PIETRANTONIO FILIPPO,MICELI ROSALBA,RAIMONDI ALESSANDRA,et al.Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer［J］.J Clin Oncol,2019,37(35):3392-3400.
［41］SHITARA K,VAN CUTSEM E,BANG YJ,et al.Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line,advanced gastric cancer:The KEYNOTE-062 phase 3 randomized clinical trial［J］.JAMA Oncol,2020,6(10):1571-1580.
［42］CHAN WL,LAM KO,LEE VHF,et al.Gastric cancer-from aetiology to management:Differences between the east and the west［J］.Clin Oncol(R Coll Radiol),2019,31(8):570-577.
［43］LIN SJ,GAGNON-BARTSCH JA,TAN IB,et al.Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas［J］.Gut,2015,64(11):1721-1731.
［44］WILKE HANSJOCHEN,MURO KEI,VAN CUTSEM ERIC,et al.Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma(RAINBOW):A double-blind,randomised phase 3 trial［J］.Lancet Oncol,2014,15(11):1224-1235.
［45］KIM ST,CRISTESCU R,BASS AJ,et al.Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer［J］.Nat Med,2018,24(9):1449-1458.
［46］PECTASIDES E,STACHLER MD,DERKS S,et al.Genomic heterogeneity as a barrier to precision medicine in gastroesophageal adenocarcinoma［J］.Cancer Discov,2018,8(9):37-48.